Immutep Overview
- Year Founded
-
1987
- Status
-
Public
- Employees
-
46
- Stock Symbol
-
IMM
- Investments
-
1
- Share Price
-
$0.02
- (As of Wednesday Closing)
Immutep General Information
Description
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Contact Information
Website
www.immutep.comCorporate Office
- Level 32, Suite 32.07 Australia Square
- 264 George Street
- Sydney, New South Wales 2000
- Australia
Corporate Office
- Level 32, Suite 32.07 Australia Square
- 264 George Street
- Sydney, New South Wales 2000
- Australia
Immutep Timeline
Immutep Stock Performance
As of 18-Nov-2026, Immutep’s stock price is $0.02. Its current market cap is $22.8M with 1.47B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.01 - $0.32 | $22.8M | 1.47B | 9.8M |
Immutep Financials Summary
As of 30-Sep-2026, Immutep has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | (12,383) | (13,635) | 125,259 | 217,066 |
| Revenue | 9,861 | 0 | 0 | |
| EBITDA | (54,038) | (41,600) | (29,036) | |
| Net Income | (53,723) | (39,749) | (27,994) | |
| Total Assets | 57,304 | 102,540 | 134,736 | |
| Total Debt | 721 | 1,062 | 1,065 |
Immutep Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immutep Patents
Immutep Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| DE-7306548-U | Fastening element for two crossing beams | Inactive | 21-Feb-1973 |
Immutep Signals
Immutep Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immutep Acquisitions (1)
Immutep’s most recent deal was a Merger/Acquisition with Immutep (acquired) for . The deal was made on 17-Dec-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Immutep (acquired) | 17-Dec-2014 | Merger/Acquisition | Drug Discovery |
Immutep ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Immutep FAQs
-
When was Immutep founded?
Immutep was founded in 1987.
-
Where is Immutep headquartered?
Immutep is headquartered in Sydney, Australia.
-
What is the size of Immutep?
Immutep has 46 total employees.
-
What industry is Immutep in?
Immutep’s primary industry is Drug Discovery.
-
Is Immutep a private or public company?
Immutep is a Public company.
-
What is Immutep’s stock symbol?
The ticker symbol for Immutep is IMM.
-
What is the current stock price of Immutep?
As of 18-Nov-2026 the stock price of Immutep is $0.02.
-
What is the current market cap of Immutep?
The current market capitalization of Immutep is $22.8M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process